The American Journal of Endocannabinoid Medicine, focused on science, knowledge and research, completed a pilot study with the objective of measuring the bioavailability of equivalent amounts cannabidiol (CBD, 10 mg) as a stand-alone active ingredient compared with a liposomal preparation (CELLg8® Hemp).
This pharmacokinetic pilot study included 15 healthy patients who were not taking a CBD product at baseline. A crossover study design was used to analyze peak blood CBD levels at baseline and 1 hour after ingesting the liposomal and nonliposomal preparations, with a 2-week washout period between each preparation.
CBD was detected in the blood of all 15 patients who ingested the liposomal preparation at 1 hour, whereas the stand-alone ingredient was only found in 40% of the individuals at the same time point. Serum levels of CBD were significantly higher (P<0.0001) in patients after use of the liposomal preparation compared with the stand-alone CBD.
The findings suggest that the bioavailability of oral CBD is higher in the liposomal preparation than the nonliposomal CBD preparation.